FLUOGUIDE A/S DK -1 (F:96X) — Market Cap & Net Worth
Market Cap & Net Worth: FLUOGUIDE A/S DK -1 (96X)
FLUOGUIDE A/S DK -1 (F:96X) has a market capitalization of $50.27 Million (€43.00 Million) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #21823 globally and #1942 in its home market, demonstrating a -1.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying FLUOGUIDE A/S DK -1's stock price €2.63 by its total outstanding shares 16349313 (16.35 Million). Review FLUOGUIDE A/S DK -1 balance sheet liabilities to assess the company's total debt and financial obligations.
FLUOGUIDE A/S DK -1 Market Cap History: 2021 to 2026
FLUOGUIDE A/S DK -1's market capitalization history from 2021 to 2026. Data shows change from $159.03 Million to $50.27 Million (-26.46% CAGR).
FLUOGUIDE A/S DK -1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how FLUOGUIDE A/S DK -1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 96X by Market Capitalization
Companies near FLUOGUIDE A/S DK -1 in the global market cap rankings as of August 5, 2026.
Key companies related to FLUOGUIDE A/S DK -1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
FLUOGUIDE A/S DK -1 Historical Marketcap From 2021 to 2026
Between 2021 and today, FLUOGUIDE A/S DK -1's market cap moved from $159.03 Million to $ 50.27 Million, with a yearly change of -26.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €50.27 Million | -14.61% |
| 2025 | €58.87 Million | -1.60% |
| 2024 | €59.83 Million | -37.40% |
| 2023 | €95.57 Million | +52.91% |
| 2022 | €62.50 Million | -60.70% |
| 2021 | €159.03 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of FLUOGUIDE A/S DK -1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $50.27 Million USD |
| MoneyControl | $50.27 Million USD |
| MarketWatch | $50.27 Million USD |
| marketcap.company | $50.27 Million USD |
| Reuters | $50.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more